Vivos Therapeutics, Inc. (VVOS)

NASDAQ: VVOS · Real-Time Price · USD

0.1727

+0.0041 (2.43%)

At close: Sep 2, 2026, 4:00 PM EDT

0.1696

-0.0031 (-1.80%)

Pre-market: Sep 3, 2026, 8:30 AM EDT

Vivos Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1.77	2.03	6.26	1.64	3.52	24.03
Cash & Short-Term Investments	1.77	2.03	6.26	1.64	3.52	24.03
Cash Growth	-59.70%	-67.59%	281.01%	-53.31%	-85.36%	31.99%
Accounts Receivable	1.44	1.58	0.43	0.2	0.46	1.72
Receivables	1.44	1.58	0.43	0.2	0.46	1.72
Prepaid Expenses	1	0.77	0.78	0.62	1.45	1.58
Total Current Assets	4.21	4.38	7.47	2.46	5.42	27.32
Property, Plant & Equipment	7.45	7.92	4.34	4.7	4.78	2.83
Goodwill	8.57	8.57	2.84	2.84	2.84	2.84
Other Intangible Assets	3.64	4.05	0.41	0.42	0.3	0.34
Other Long-Term Assets	0.27	0.23	0.22	0.31	0.37	0.36
Total Assets	24.14	25.15	15.28	10.73	13.72	33.69

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	2.95	1.68	1.1	2.15	1.41	0.92
Accrued Expenses	7.04	5.99	2.23	2.33	1.91	2.85
Current Portion of Long-Term Debt	7.77	8.35	-	-	-	1.27
Current Portion of Leases	0.85	0.73	0.48	0.47	0.42	-
Current Unearned Revenue	0.58	0.48	0.9	2.14	2.93	2.4
Other Current Liabilities	1.2	0.85	0.27	0.2	0.15	0.07
Total Current Liabilities	20.39	18.08	4.98	7.29	6.81	7.51
Long-Term Debt	0.37	0.47	-	-	-	-
Long-Term Leases	3.52	3.95	1.04	1.52	1.99	-
Long-Term Unearned Revenue	-	-	0.1	0.29	0.11	-
Other Long-Term Liabilities	3.85	4.2	1.22	1.22	-	0.64
Total Liabilities	28.13	26.7	7.33	10.32	8.92	8.15

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0	0	-	-	-	0
Additional Paid-In Capital	133.6	123.87	112.14	93.46	84.27	81.16
Retained Earnings	-138.52	-125.36	-104.19	-93.05	-79.47	-55.62
Total Common Equity	-4.92	-1.49	7.95	0.41	4.8	25.54
Minority Interest	-0.17	-0.06	-	-	-	-
Shareholders' Equity	-3.99	-1.55	7.95	0.41	4.8	25.54
Total Liabilities & Equity	24.14	25.15	15.28	10.73	13.72	33.69

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	12.51	13.5	1.51	2	2.41	1.27
Net Cash (Debt)	-10.73	-11.47	4.75	-0.35	1.11	22.77
Net Cash Growth	-	-	-	-	-95.14%	34.58%
Net Cash Per Share	-0.77	-1.12	0.95	-0.29	1.20	26.80
Filing Date Shares Outstanding	20.12	13.49	5.89	2.73	1.19	0.92
Total Common Shares Outstanding	14.53	9.29	5.89	1.83	0.92	0.92
Working Capital	-16.18	-13.69	2.5	-4.83	-1.39	19.82
Book Value Per Share	-0.34	-0.16	1.35	0.22	5.22	27.75
Tangible Book Value	-17.13	-14.11	4.7	-2.85	1.66	22.36
Tangible Book Value Per Share	-1.18	-1.52	0.80	-1.56	1.80	24.29
Machinery	3.64	3.5	1.76	1.73	1.41	1.47
Construction In Progress	-	-	1.86	1.44	0.95	0.21
Leasehold Improvements	3.49	3.2	2.48	2.48	2.48	2.39

SEC Filings: 10-K · 10-Q